BRPI0608381A2 - compostos aprimorados farmacocineticamente - Google Patents

compostos aprimorados farmacocineticamente

Info

Publication number
BRPI0608381A2
BRPI0608381A2 BRPI0608381-1A BRPI0608381A BRPI0608381A2 BR PI0608381 A2 BRPI0608381 A2 BR PI0608381A2 BR PI0608381 A BRPI0608381 A BR PI0608381A BR PI0608381 A2 BRPI0608381 A2 BR PI0608381A2
Authority
BR
Brazil
Prior art keywords
lower alkyl
acylamino
alkylthio
carbonyl
starch
Prior art date
Application number
BRPI0608381-1A
Other languages
English (en)
Inventor
Stewart Campbell
David Duffy
Michael Grogan
Steven Kates
Emanuele Ostuni
Olivier Schueller
Paul Sweetnam
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of BRPI0608381A2 publication Critical patent/BRPI0608381A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS APRIMORADOS FARMACOCINETICAMENTE. Um composto da fórmula A com características de ligação não específicas e propriedades farmacocinétícas aprimoradas é fornecido: ou sal aceitável farmaceuticamente, estereoisómero ou seu hidrato, em que Ri é alquíl inferior, R2 e R3 são selecionados independentemente de alquil inferior e alquenil inferior e alquinil inferior, em que o alquil inferior, o alquenil inferior e o alquinil inferior podem ser opcionalmente substituidos por um ou mais halogêneos, alcóxi inferior, hidróxi, CN, N02, amíno, acilamino, amido, carbonil e alquiltio, A é N ou C-H, B é N, C-H, C-(S02-R4), ou C-CO-R4, D é N, C-H, C-(S02-R4) ou C-CO-R4, E é N ou C-H, em que somente um entre A, B ou E pode ser N, e um entre B ou D é C-(S02-R4) ou C-CO-R4, R4 é um grupo que tem a fórmula: em que cada R, R, R e R são independentemente selecionados de H e alquil inferior, em que o alquil inferior pode ser opcionalmente substituído por um ou mais halogênios, alcóxi inferior, hidróxi, CN, NO~ 2~, amino, acilamino, amido, carbonil e alquiltio; e, além de, ou como alternativa, R^ 6^ e R^ 5^ formam, juntos, anel de 5 ou 6 membros, ou R^ 6^ e R^ 7^ formam, juntos, um anel de 3 a 6 membros; R^ 9^ e selecionado independentemente de H e alquil inferior, em que o alquil inferior pode ser opcionalmente substituído por um ou mais halogênios, alcóxi inferior, hidróxi, CN, NO~ 2~, amino, acílamino, amido, carbonil e alquiltio; alternativamente R e R juntos com o nitrogênio ao qual estão anexados formam um anel de 5 ou 6 membros; n é de 1 a 4; e m é de 1 a 6.
BRPI0608381-1A 2005-02-18 2006-02-21 compostos aprimorados farmacocineticamente BRPI0608381A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65393305P 2005-02-18 2005-02-18
PCT/US2006/006048 WO2006089276A2 (en) 2005-02-18 2006-02-21 Pharmacokinetically improved compounds

Publications (1)

Publication Number Publication Date
BRPI0608381A2 true BRPI0608381A2 (pt) 2009-12-29

Family

ID=36917159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608381-1A BRPI0608381A2 (pt) 2005-02-18 2006-02-21 compostos aprimorados farmacocineticamente

Country Status (19)

Country Link
US (2) US20080176844A1 (pt)
EP (1) EP1850853A4 (pt)
JP (1) JP2008530247A (pt)
KR (1) KR20080016531A (pt)
CN (2) CN102351862A (pt)
AU (1) AU2006213985C1 (pt)
BR (1) BRPI0608381A2 (pt)
CA (1) CA2598271A1 (pt)
CR (1) CR9381A (pt)
EA (1) EA018668B1 (pt)
GE (1) GEP20115184B (pt)
IL (1) IL185344A0 (pt)
MX (1) MX2007010144A (pt)
NI (1) NI200700210A (pt)
NO (1) NO20074742L (pt)
NZ (1) NZ560963A (pt)
UA (1) UA90502C2 (pt)
WO (1) WO2006089276A2 (pt)
ZA (1) ZA200707505B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598270A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2010065617A1 (en) * 2008-12-02 2010-06-10 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) * 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) * 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5359115A (en) * 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5440016A (en) * 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5362899A (en) * 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
PT1049695E (pt) * 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
US5958886A (en) * 1998-01-13 1999-09-28 Sigma-Tau Pharmaceuticals, Inc. Carnitine-containing peptides and a method for using the same
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
KR20020062770A (ko) * 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 이미다조 1,3,5 트리아지논 및 그의 용도
AU2841801A (en) * 1999-12-24 2001-07-09 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6794387B2 (en) * 2001-03-28 2004-09-21 Pfizer Inc. Pharmaceutically active compounds

Also Published As

Publication number Publication date
AU2006213985B2 (en) 2011-08-25
CA2598271A1 (en) 2006-08-24
CR9381A (es) 2008-06-19
NI200700210A (es) 2008-07-24
EP1850853A2 (en) 2007-11-07
JP2008530247A (ja) 2008-08-07
EP1850853A4 (en) 2011-09-07
NZ560963A (en) 2010-11-26
CN102351862A (zh) 2012-02-15
EA018668B1 (ru) 2013-09-30
KR20080016531A (ko) 2008-02-21
CN101223171A (zh) 2008-07-16
AU2006213985C1 (en) 2012-03-15
ZA200707505B (en) 2009-08-26
US20080176844A1 (en) 2008-07-24
NO20074742L (no) 2007-11-16
EA200701753A1 (ru) 2008-04-28
GEP20115184B (en) 2011-03-25
WO2006089276A2 (en) 2006-08-24
WO2006089276A3 (en) 2006-12-21
CN101223171B (zh) 2011-09-14
MX2007010144A (es) 2008-02-15
UA90502C2 (ru) 2010-05-11
US20100093719A1 (en) 2010-04-15
IL185344A0 (en) 2008-02-09
AU2006213985A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
RS51834B (en) DIAZABICYCLOALKAN AMIDES SELECTIVE ON THE SUBSTANCE OF NICOTINE ACETYLHOLINE RECEPTORS
MXPA05012248A (es) Fenil quinolinas y su uso como moduladores del receptor de estrogeno.
MA26905A1 (fr) Derives de phenylglycine.
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
ATE383856T1 (de) (4-hydroxyphenyl)-1h-indol-3-carbaldehydoxim- derivative als östrogenagentien
MXPA05010652A (es) Pirazoles sustituidos.
BRPI0508703B8 (pt) processo para a síntese de um antagonista de cxcr4
ATE431333T1 (de) Amino-propanolderivate
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
BRPI0608381A2 (pt) compostos aprimorados farmacocineticamente
AR028647A1 (es) Derivados de 1,4-diazabiciclo[3.2.2]nonano benzoxazol, benzotiazol y bencimidazol, su preparacion y su aplicacion en terapéutica
MXPA05010651A (es) Compuestos de pirazol.
DE602004009056D1 (de) N-(2-phenylethyl)sulfamid-derivate als integrin-alpha4-antagonisten
BRPI0518998A2 (pt) âmega-feniloctanamidas
AR067718A1 (es) Compuesto de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-0-sustituida, compuesto intermedio para la preparacion del mismo y su uso como tal, proceso para la preparacion del compuesto, y su uso para la preparacion de un medicamento
AR007814A1 (es) Un compuesto derivado de benzo[g]quinolina, uso del mismo, un proceso para prepararlo y una composicion farmaceutica que lo comprende.
ATE448216T1 (de) Tetralin- und indanderivate und anwendungen davon
UA97237C2 (ru) Производные таксола с противоопухолевой активностью

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.